WallStreetZenWallStreetZen

NASDAQ: ESPR
Esperion Therapeutics Inc Stock Ownership - Who owns Esperion Therapeutics?

Insider buying vs selling

Have Esperion Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Eric WarrenChief Commercial Officer2024-05-17192$2.48
$476.74Sell
Eric WarrenChief Commercial Officer2023-09-20742$1.25
$923.79Sell
Eric WarrenChief Commercial Officer2023-08-18243$1.41
$343.60Sell
Eric WarrenChief Commercial Officer2023-07-19106$1.59
$168.01Sell
Eric WarrenChief Commercial Officer2023-06-21603$1.48
$894.25Sell

1 of 1

ESPR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ESPR insiders and whales buy or sell their stock.

ESPR Shareholders

What type of owners hold Esperion Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC7.24%13,708,731$39.62MInstitution
Bellevue Group Ag5.25%9,944,064$28.74MInstitution
Wasatch Advisors LP4.82%9,129,647$26.38MInstitution
Vanguard Group Inc4.66%8,826,546$25.51MInstitution
Great Point Partners LLC4.22%8,000,000$23.12MInstitution
Woodline Partners LP4.18%7,922,229$22.90MInstitution
Millennium Management LLC3.00%5,681,744$16.42MInstitution
D E Shaw Co Inc2.71%5,143,486$14.86MInstitution
Bank Of America Corp2.40%4,545,260$13.14MInstitution
Target N. V. Biotech2.36%4,477,964$12.94MInsider

1 of 3

ESPR vs Pharmaceutical Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ESPR66.12%20.81%Net SellingNet Selling
SIGA35.16%64.84%Net SellingNet Selling
CGC7.76%92.24%Net SellingNet Selling
HROW28.65%71.35%Net SellingNet Buying
PETQ83.52%16.48%Net SellingNet Selling

Esperion Therapeutics Stock Ownership FAQ

Who owns Esperion Therapeutics?

Esperion Therapeutics (NASDAQ: ESPR) is owned by 66.12% institutional shareholders, 20.81% Esperion Therapeutics insiders, and 13.07% retail investors. Target N. V. Biotech is the largest individual Esperion Therapeutics shareholder, owning 4.48M shares representing 2.36% of the company. Target N. V. Biotech's Esperion Therapeutics shares are currently valued at $13.03M.

If you're new to stock investing, here's how to buy Esperion Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.